THE ROLE OF OBESITY AND PLASMA ADIPOCYTOKINES IN IMMUNE DYSREGULATION IN SEPSIS PATIENTS

ABSTRACT Introduction: The dysregulated immune response in sepsis is highly variable, ranging from hyperinflammation to immunoparalysis. Obesity is associated with the release of inflammatory mediators from adipose tissue, known as adipocytokines, causing a chronic inflammatory state. Perhaps counterintuitively, obesity is also associated with lower mortality in sepsis patients. We investigated the association between obesity, circulating adipocytokine concentrations, immune dysregulation, and outcome in sepsis patients. Methods In this secondary analysis of a prospective study, plasma concentrations of the adipocytokines leptin, adiponectin, and resistin were assessed in 167 patients at diagnosis of sepsis due to pneumonia, bacteremia, or acute cholangitis. Adipocytokines were compared between patients with normal weight (body mass index [BMI], 18.5–24.9 kg/m2; n = 67), overweight (BMI, 25.0–29.9 kg/m2; n = 56), and obesity (BMI ≥30 kg/m2; n = 42), as well as between immunological endotypes: hyperinflammation (n = 40), immunoparalysis (n = 62), and unclassified (n = 55). Results: Higher circulating concentrations of leptin were observed in patients with obesity compared with patients with normal weight (P = 0.008) and overweight (P = 0.02), whereas adiponectin and resistin plasma concentrations were not different (P = 0.08 and P = 0.85, respectively). Resistin concentrations were associated with immunological endotypes, with the highest levels found in hyperinflammatory patients (P < 0.001). Furthermore, resistin concentrations were predictive for 28-day mortality (adjusted odds ratio, 1.03 per 10 ng/mL; P = 0.04). These associations were not found for leptin and adiponectin. Conclusion: Obesity and BMI-related adipocytokines are not related to the development of a hyperactive or suppressed immune response as defined by ferritin and mHLA-DR expression in sepsis patients. Although resistin is related to the immune response and an increased risk of adverse clinical outcomes, these associations are similar in patients with normal weight, overweight, and obesity. This implies that the relationship between resistin and clinical outcome is likely driven by the inflammatory response and not by obesity itself. Taken together, although there exists a strong association between inflammation and sepsis mortality, our results do not point toward a role for obesity and BMI-related adipocytokines in immune dysregulation in sepsis patients.

[1]  L. Joosten,et al.  Adipocytokine plasma concentrations reflect influence of inflammation but not body mass index (BMI) on clinical outcomes of COVID‐19 patients: A prospective observational study from the Netherlands , 2022, Clinical obesity.

[2]  A. Koutsoukou,et al.  Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial , 2022, Cell reports. Medicine.

[3]  C. Lang,et al.  Resistin production does not affect outcomes in a mouse model of acute surgical sepsis , 2022, PloS one.

[4]  D. Khanna,et al.  Obesity: A Chronic Low-Grade Inflammation and Its Markers , 2022, Cureus.

[5]  H. Gelissen,et al.  Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial. , 2021, JAMA.

[6]  N. D. de Keizer,et al.  Body Mass Index and Mortality in Coronavirus Disease 2019 and Other Diseases: A Cohort Study in 35,506 ICU Patients , 2021, Critical care medicine.

[7]  Toshio Tanaka,et al.  Adipocytokine Profile Reveals Resistin Forming a Prognostic-Related Cytokine Network in the Acute Phase of Sepsis , 2021, Shock.

[8]  A. Malhotra,et al.  Obesity and Critical Illness in COVID‐19: Respiratory Pathophysiology , 2021, Obesity.

[9]  M. Jaeger,et al.  A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients , 2021, International Journal of Obesity.

[10]  M. Hedrick,et al.  A flow cytometric assay for HLA‐DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials , 2021, Cytometry. Part B, Clinical cytometry.

[11]  C. Lang,et al.  Resistin directly inhibits bacterial killing in neutrophils , 2019, Intensive Care Medicine Experimental.

[12]  P. Żelechowska,et al.  Adipocytokine Involvement in Innate Immune Mechanisms. , 2018, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  M. Lazar,et al.  Human resistin protects against endotoxic shock by blocking LPS–TLR4 interaction , 2017, Proceedings of the National Academy of Sciences.

[14]  S. Orfanos,et al.  Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis , 2017, BMC Medicine.

[15]  M. Netea,et al.  The immunopathology of sepsis and potential therapeutic targets , 2017, Nature Reviews Immunology.

[16]  Liu Shuying,et al.  “Obesity Paradox” in Acute Respiratory Distress Syndrome: Asystematic Review and Meta-Analysis , 2016, PloS one.

[17]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[18]  E. Solomou,et al.  The role of obesity in the immune response during sepsis , 2014, Nutrition & Diabetes.

[19]  E. Abraham,et al.  Human Resistin Promotes Neutrophil Proinflammatory Activation and Neutrophil Extracellular Trap Formation and Increases Severity of Acute Lung Injury , 2014, The Journal of Immunology.

[20]  S. Jee,et al.  Obesity survival paradox in pneumonia: a meta-analysis , 2014, BMC Medicine.

[21]  Zi-hui Deng,et al.  Diagnostic value of serum leptin and a promising novel diagnostic model for sepsis , 2014, Experimental and therapeutic medicine.

[22]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[23]  Wei-Yen Hsu,et al.  Resistin induces monocyte–endothelial cell adhesion by increasing ICAM‐1 and VCAM‐1 expression in endothelial cells via p38MAPK‐dependent pathway , 2011, Journal of cellular physiology.

[24]  I. Hickman,et al.  Changes in serum adiponectin concentrations in critical illness: a preliminary investigation , 2009, Critical care.

[25]  Christian Trautwein,et al.  Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients , 2009, Critical care.

[26]  W. Hörl,et al.  Resistin Inhibits Essential Functions of Polymorphonuclear Leukocytes , 2008, The Journal of Immunology.

[27]  K. Walsh,et al.  Adiponectin as an anti-inflammatory factor. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[28]  C. Meisel,et al.  Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. , 2005, Clinical chemistry.

[29]  U. Smith,et al.  Resistin, an Adipokine with Potent Proinflammatory Properties1 , 2005, The Journal of Immunology.

[30]  H. Tilg,et al.  Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. , 2003, Biochemical and biophysical research communications.

[31]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[32]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[33]  A. La Cava Leptin in inflammation and autoimmunity , 2017, Cytokine.